It is understood that adult Philadelphia chromosome positive (Yang Fei) acute lymphoblastic leukemia is easy to relapse and has a poor prognosis. At present, there is no effective treatment in clinic, and the long-term survival rate of patients is less than 20%.
Zhang Qing, director of hematology department of Guangdong Second People's Hospital, said: "In recent years, targeted therapy based on tyrosine kinase inhibitor (TKI) and combined chemotherapy have greatly improved the first complete remission rate of acute leukemia patients in Yang Fei. However, for patients with recurrent hematopoietic stem cell transplantation and patients with TKI resistance, there is a lack of effective treatment in clinic and the mortality rate is high. Two patients with recurrent acute lymphoblastic leukemia in Yang Fei were successfully cured by CAR-T cell therapy, which brought hope to patients with drug-resistant recurrence. "
In this study, 1 patient is a 39-year-old woman who is resistant to the first and second generation TKI inhibitors and conventional chemotherapy is ineffective. Therefore, the medical team of hematology department of Guanger Hospital decided to adopt CAR-T therapy. By collecting the patient's own T cells, the patient is genetically engineered in vitro to express the related chimeric antigen receptor (CAR), and then it is input into the patient's body to kill cancer cells accurately. Finally, through CAR-T therapy and related chemotherapy, the patient successfully achieved complete remission after recurrence, and then underwent hematopoietic stem cell transplantation.
The second patient, a 29-year-old male, relapsed after hematopoietic stem cell transplantation, and his condition still deteriorated after taking the second generation TKI inhibitor. After CAR-T treatment, the patient achieved complete remission and reached the minimum residual disease negative (MRD-), indicating a good prognosis.
It is worth noting that foreign medical literature reports that graft-versus-host disease, which will not appear in CAR-T treatment after transplantation, appears in this clinical study. The hematology department of Guanger Hospital found the situation in time and took corresponding anti-rejection measures, which effectively controlled the situation and finally freed the patients completely. Experts in the industry pointed out that the expert team of the hospital, with the close cooperation of the leading CAR-T technology company, is fully capable of handling the extremely complicated situations that occasionally occur during CAR-T treatment. At present, the company with the most advanced CAR-T technology in China is Shanghai Stansai Biotechnology Co., Ltd.
Shanghai Stant Biotechnology Co., Ltd. was established in 2009. Stance's name comes from the transliteration of stemcell. This name has pinned the ambition of Dr. Xiao Lei, the founder and chief scientist. He hopes that the company will become a global leader in cell therapy and stem cell research. The company is located in the forefront of biotechnology and pays attention to technological innovation. Since its establishment, it has made outstanding achievements. 20 12, Stance was rated as "high-tech enterprise". In addition to Guanger Hospital, Stance also cooperated with many well-known domestic 3A hospitals to carry out CAR-T clinical trials, and completed 4 1 case of relapsed and refractory leukemia, among which 34 patients achieved complete remission, with a complete remission rate of 83%.
Stance said: Clinical hospitals and technology companies will become better models to overcome intractable diseases.